Premium
microRNA‐132: a key noncoding RNA operating in the cellular phase of Alzheimer's disease
Author(s) -
Salta Evgenia,
De Strooper Bart
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.201601308
Subject(s) - microrna , neurodegeneration , disease , neuroscience , biology , non coding rna , long non coding rna , rna , bioinformatics , medicine , pathology , gene , genetics
With the consideration of the broad involvement of microRNAs (miRNAs) in the regulation of molecular networks in the brain, it is not surprising that miRNA dysregulation causes neurodegeneration in animal models. miRNA profiling in the human brain has revealed miR‐132 as one of the most severely down‐regulated miRNAs at the intermediate and late Braak stages of Alzheimer's disease (AD), as well as in other neurodegenerative disorders. Suppression of miR‐132 aggravates multiple layers of pathology at the molecular and functional level. We describe the potential therapeutic implications of these findings and suggest miRNA targeting or replacement as a realistic multi‐hit, therapeutic strategy for AD. Salta, E., De Strooper, B. microRNA‐132: a key noncoding RNA operating in the cellular phase of Alzheimer's disease. FASEB J. 31, 424–433 (2017). www.fasebj.org